Viewing nowPMS Pregabalin Capsule 150 mg
Pregabalin 150mg
Hard capsule · Prescription medication
PharmaScience Korea Co., Ltd.

MFDS item code 201605666 · Approved 2016.09.27 · Insurance code 627600160
Treatment of neuropathic pain and fibromyalgia, and adjunctive treatment of partial-onset seizures
This drug is used to treat peripheral and central neuropathic pain in adults. It is also used as an adjunct in epilepsy patients experiencing partial seizures, regardless of the presence of secondary generalization. Additionally, it helps relieve symptoms in patients with fibromyalgia. It is effectively used for various neurological disorders.
Administer the total daily dose of pregabalin orally in 2 divided doses, with or without food. Since this drug is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg per day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg per day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This drug may be administered at an initial dose of 150 mg per day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg-450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies were also conducted at a dose of 600 mg per day; however, there is no evidence of additional benefit or adequate tolerability at this dose. Considering the dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this drug is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this drug is primarily excreted by the kidneys unchanged. Since the clearance of this drug is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. This drug is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose determined by renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Administration regimen Initial dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30-<60 75 300 BID or TID ≥15-<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as specified in the administration regimen. b: Supplemental dose refers to an additional dose administered as a single dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (aged 65 years and older) Dose reduction may be necessary in older adults with impaired renal function.
7. Pediatric and adolescent patients Administration is not recommended for children under 12 years of age or adolescent patients aged 12-17 years because there are insufficient safety and efficacy data.
This medication may increase the risk of suicidal thoughts or behaviors, so mood changes or abnormal behavior signs should be closely monitored during treatment. It should not be taken by those allergic to its ingredients, and patients with certain genetic metabolic disorders should avoid it. Diabetic patients may need to adjust the dosage of their blood glucose medications due to weight gain after taking this drug. If severe allergic reactions such as angioedema occur, use should be discontinued immediately, and medical advice should be sought. Elderly patients should be cautious as there is a risk of falls or injuries due to dizziness or drowsiness from this medication. Blurry vision or changes in vision may occur; if these symptoms arise, the medication should be discontinued and a doctor consulted. Abrupt discontinuation of this drug can result in withdrawal symptoms such as insomnia, headache, and anxiety, so the dosage should be gradually reduced according to a doctor's instructions. There is a risk of drug abuse; therefore, patients with a history of substance abuse should use it with caution. Patients with impaired kidney function should have their dosage adjusted, and those with heart failure should use it carefully. When used in combination with other drugs that have central nervous system depressant effects, there is an increased risk of respiratory depression, so caution is advised. Pregnant women should avoid use in early pregnancy to reduce the risk of fetal malformations, and women of childbearing age should use effective contraception. Breastfeeding women are advised to discontinue either breastfeeding or the medication since it may be transferred through breast milk. Activities requiring concentration, such as driving or operating machinery, should be avoided until dizziness or drowsiness has completely resolved after taking this medication. In case of overdose, symptoms such as confusion, drowsiness, and seizures may occur, and immediate medical treatment is required. This medication should be kept out of the reach of children and not transferred to other containers for safety.
suicidal ideation, suicidal behavior, depression, angioedema, facial swelling, perioral edema, upper airway edema, dizziness, drowsiness, loss of consciousness, confusion, mental disorder, blurred vision, changes in vision, insomnia, headache, nausea, anxiety, diarrhea, influenza-like illness, restlessness, suicidal thoughts, pain, seizures, hyperhidrosis, misuse, abuse, dependence, weight gain, rhinitis, neutropenia, increased appetite, loss of appetite, hypoglycemia, confusion, disorientation, irritability, depression, relief, decreased libido, insomnia, derealization, paraphilia, restlessness, anxiety, mood disturbances, low emotional tone, elevated mood, hallucinations, abnormal dreams, increased libido, panic attacks, inability to inhibit, apathy, ataxia, motor coordination abnormalities, balance disorders, amnesia, attention deficit, memory disorders, tremors, speech disorders, sensory abnormalities, sensory loss, sedation, drowsiness, cognitive impairment, nystagmus, language disorders, tonic-clonic convulsions, decreased reflexes, motor abnormalities, psychomotor agitation, position-related dizziness, hypersensitivity, burning sensation, tremors during activity, syncope, confusion, hypokinesia, olfactory abnormalities, taste loss, writing disability, blurred vision, diplopia, indirect vision loss, visual disturbances, visual defects, photophobia, dry eyes, eye swelling, decreased visual acuity, eye pain, eye fatigue, increased tear secretion, eye irritation, mydriasis, vibration-induced changes in depth perception, strabismus, brightness perception, vertigo, auditory hypersensitivity, first-degree atrioventricular block, tachycardia, sinus bradycardia, sinus tachycardia, sinus arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, dyspnea, epistaxis, cough, nasal congestion, rhinitis, snoring, throat tension, nasal dryness, respiratory depression, vomiting, abdominal distension, constipation, dry mouth, bloating, excessive salivation, gastroesophageal reflux, oral sensory reduction, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweat, muscle cramps, arthralgia, back pain, limb pain, cervical spasms, joint swelling, myalgia, muscle spasms, neck pain, muscle rigidity, rhabdomyolysis, urination disorders, urinary incontinence, reduced urination, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, breast pain, nipple discharge, gynecomastia, peripheral edema, swelling, gait abnormalities, falls, feeling intoxicated, sensory abnormalities, fatigue, chest tightness, systemic edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, increased serum creatine phosphokinase, increased aspartate aminotransferase, increased blood glucose, decreased platelet count, decreased serum potassium, increased serum creatinine, decreased white blood cell count, hypersensitivity, allergic reactions, headache, keratitis, congestive heart failure, pulmonary edema, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, lethargy, delirium, paralysis (facial paralysis), affective disorder, states of confusion, agitation, restlessness, increased seizure activity, sleep disorders, skin disorders, bloody stools, increased BUN, speech disorders, ataxia, tinnitus, constipation, gastrointestinal disorders
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture, and maintaining a temperature between 15 and 30 degrees Celsius at room temperature is recommended. This storage method helps preserve the drug's effectiveness for a longer period.
Hard capsule with a white upper part and a white lower part containing white or light yellow powder
30 capsules/bottle, 100 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 150mg
Hard capsule · Prescription medication
PharmaScience Korea Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.